Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatforms for Antitumor Immunotherapy

被引:6
作者
Sui, Xueqing [1 ]
Jin, Teng [2 ]
Liu, Tonghui [3 ]
Wu, Shiman [4 ]
Wu, Yue [4 ]
Tang, Zhongmin [5 ]
Ren, Yan [4 ]
Ni, Dalong [6 ,7 ,8 ]
Yao, Zhenwei [4 ]
Zhang, Hua [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Dept Radiol, Qingdao, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Radiol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Dept Neurol, Qingdao, Peoples R China
[4] Fudan Univ, Huashan Hosp, Dept Radiol, Shanghai, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai, Peoples R China
[6] Univ Wisconsin Madison, Dept Radiol, Madison, WI 53706 USA
[7] Univ Wisconsin Madison, Dept Med Phys, Madison, WI 53706 USA
[8] Univ Wisconsin Madison, Dept Pharmaceut Sci, Madison, WI 53706 USA
来源
FRONTIERS IN CHEMISTRY | 2020年 / 8卷
基金
中国国家自然科学基金;
关键词
cancer; nanomaterials; enhanced immunotherapy; normalized immunotherapy; tumor immune microenvironment; CANCER-IMMUNOTHERAPY; TARGETED DELIVERY; T-CELLS; NANOPARTICLES; MACROPHAGES; THERAPY; HYPOXIA; IMPACT;
D O I
10.3389/fchem.2020.00804
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Interest in cancer immunotherapy has rapidly risen since it offers many advantages over traditional approaches, such as high efficiency and prevention of metastasis. Efforts have primarily focused on two major strategies for regulating the body's antitumor immune response mechanisms: "enhanced immunotherapy" that aims to amplify the immune activation, and "normalized immunotherapy" that corrects the defective immune mechanism in the tumor immune microenvironments (TIMEs), which returns to the normal immune trajectory. However, due to the complexity and heterogeneity of the TIMEs, and lack of visualization research on the immunotherapy process, cancer immunotherapy has not been widely used in clinical setting. Recently, through the design and modification of nanomaterials, intelligent TIME-responsive nanoplatforms were developed from which encouraging results in many aspects of immunotherapy have been achieved. In this mini review, the status of designed nanomaterials for nanoplatform-based immune regulation of TIMEs has been emphasized, particularly with respect to the aforementioned approaches. It is envisaged that future prospects will focus on a combination of multiple immunotherapies for more efficient cancer inhibition and elimination.
引用
收藏
页数:6
相关论文
共 43 条
[1]   Enhanced Cellular Ablation by Attenuating Hypoxia Status and Reprogramming Tumor-Associated Macrophages via NIR Light-Responsive Upconversion Nanocrystals [J].
Ai, Xiangzhao ;
Hu, Ming ;
Wang, Zhimin ;
Lyu, Linna ;
Zhang, Wenmin ;
Li, Juan ;
Yang, Huanghao ;
Lin, Jun ;
Xing, Bengang .
BIOCONJUGATE CHEMISTRY, 2018, 29 (04) :928-938
[2]   Update on the challenges and recent advances in cancer immunotherapy [J].
Baronzio, Gianfranco ;
Parmar, Gurdev ;
Shubina, Irina Z. H. ;
Cassutti, Valter ;
Giuli, Sergio ;
Ballerini, Marco ;
Kiselevsky, Mikhail .
IMMUNOTARGETS AND THERAPY, 2013, 2 :39-49
[3]   Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages [J].
Beatty, Gregory L. ;
Winograd, Rafael ;
Evans, Rebecca A. ;
Long, Kristen B. ;
Luque, Santiago L. ;
Lee, Jae W. ;
Clendenin, Cynthia ;
Gladney, Whitney L. ;
Knoblock, Dawson M. ;
Guirnalda, Patrick D. ;
Vonderheide, Robert H. .
GASTROENTEROLOGY, 2015, 149 (01) :201-210
[4]   Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology [J].
Bertrand, Nicolas ;
Wu, Jun ;
Xu, Xiaoyang ;
Kamaly, Nazila ;
Farokhzad, Omid C. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 :2-25
[5]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[6]   RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells [J].
Borkner, Lisa ;
Kaiser, Andrew ;
van de Kasteele, Willeke ;
Andreesen, Reinhard ;
Mackensen, Andreas ;
Haanen, John B. ;
Schumacher, Ton N. ;
Blank, Christian .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (08) :1173-1183
[7]   Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) [J].
Chae, Young Kwang ;
Arya, Ayush ;
Iams, Wade ;
Cruz, Marcelo R. ;
Chandra, Sunandana ;
Choi, Jaehyuk ;
Giles, Francis .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[8]   Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth [J].
Deng, Guanjun ;
Sun, Zhihong ;
Li, Sanpeng ;
Peng, Xinghua ;
Li, Wenjun ;
Zhou, Lihua ;
Ma, Yifan ;
Gong, Ping ;
Cai, Lintao .
ACS NANO, 2018, 12 (12) :12096-12108
[9]   VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity [J].
ElTanbouly, Mohamed A. ;
Croteau, Walburga ;
Noelle, Randolph J. ;
Lines, J. Louise .
SEMINARS IN IMMUNOLOGY, 2019, 42
[10]   Lack of immunoediting in murine pancreatic cancer reversed with neoantigen [J].
Evans, Rebecca A. ;
Diamond, Mark S. ;
Rech, Andrew J. ;
Chao, Timothy ;
Richardson, Max W. ;
Lin, Jeffrey H. ;
Bajor, David L. ;
Byrne, Katelyn T. ;
Stanger, Ben Z. ;
Riley, James L. ;
Markosyan, Nune ;
Winograd, Rafael ;
Vonderheide, Robert H. .
JCI INSIGHT, 2016, 1 (14)